Guardant Health's InfinityAI Real-World Evidence Supports Japan Approval Of ENHERTU For HER2-Positive Advanced Cancers Across Multiple Tumor Types

Guardant Health, Inc. (NASDAQ: GH) announced that its InfinityAI platform provided real-world evidence supporting the approval of ENHERTU (trastuzumab deruxtecan) by Japan's Ministry of Health for treating HER2-positive advanced cancers. This approval was based on data from several clinical trials and real-world evidence generated by InfinityAI, highlighting the importance of real-world data in identifying patients with rare biomarkers. The collaboration with Daiichi Sankyo demonstrates a new approach to complement clinical trial data with real-world insights, particularly in genomic subpopulations.